Intracranial hypotension (IH), often resulting from a cerebrospinal fluid (CSF) leak, is a notable cause of secondary headaches. Diagnosing IH through clinical assessment and neuroimaging can be challenging. Orthostatic headache (OH), characterized by neck stiffness, nausea, dizziness, phonophobia, and photophobia, is a key symptom of CSF leakage, which may stem from a variety of causes, including falling, surgery, CSF studies, or arachnoid diverticula. This study presents two OH patients with IH who were incidentally found to have an underlying meningocele.

Intracranial hypotension (IH), often resulting from a cerebrospinal fluid (CSF) leak, is a notable cause of secondary headaches. Diagnosing IH through clinical assessment and neuroimaging can be challenging. Orthostatic headache (OH), characterized by neck stiffness, nausea, dizziness, phonophobia, and photophobia, is a key symptom of CSF leakage, which may stem from a variety of causes, including falling, surgery, CSF studies, or arachnoid diverticula. This study presents two OH patients with IH who were incidentally found to have an underlying meningocele.

Intracranial hypotension (IH), often resulting from a cerebrospinal fluid (CSF) leak, is a notable cause of secondary headaches. Diagnosing IH through clinical assessment and neuroimaging can be challenging. Orthostatic headache (OH), characterized by neck stiffness, nausea, dizziness, phonophobia, and photophobia, is a key symptom of CSF leakage, which may stem from a variety of causes, including falling, surgery, CSF studies, or arachnoid diverticula. This study presents two OH patients with IH who were incidentally found to have an underlying meningocele.

Objective: There is insufficient data on the etiology of altered mental status (AMS). This study aimed to classify the causes of AMS in patients transported by the 119 emergency medical services (EMS) and analyze the characteristics of vital signs. Methods: We enrolled patients with AMS based on the Glasgow Coma Scale (GCS) score <15, who were transferred to the emergency department by 119 EMS. The causes of AMS were determined through a retrospective review of their medical records. Results: A total of 2,730 patients were enrolled. The major causes for AMS were stroke (19.9%), intoxication (17.7%), traumatic brain injury (9.6%), sepsis (6.4%), and seizures (6.3%). The proportion of non-central nervous system (non-CNS) causes was higher than CNS-related causes (72.4% vs. 27.6%, P<0.001). The proportion of patients with shock was 6.2%. Age >60 years (odds ratio [OR]=2.30; 95% confidence interval [CI], 1.77-3.00), female (OR=0.69; 95% CI, 0.55-0.87), GCS <9 (OR=1.96; 95% CI, 1.57-2.46), systolic blood pressure (SBP) <90 mmHg (OR=2.96; 95% CI, 2.04-4.29), SBP ≥180 mmHg (OR=1.73; 95% CI, 1.29-2.32), respiratory rate >20/min (OR=1.72; 95% CI, 1.34-2.20), saturation <94% (OR, 1.89; 95% CI, 1.46-2.44), body temperature >37.5 Conclusion The etiologies of AMS in patients were varied. Non-CNS causes were more prevalent than CNS-related causes. Approximately 6% of patients met the criteria for shock.

Purpose: Although osimertinib is the standard-of-care treatment of epidermal growth factor receptor (EGFR) T790M mutation–positive non–small cell lung cancer, real-world evidence on the efficacy of osimertinib is not enough to reflect the complexity of the entire course of treatment. Herein, we report on the use of osimertinib in patients with EGFR T790M mutation–positive non–small cell lung cancer who had previously received EGFR tyrosine kinase inhibitor (TKI) treatment in Korea. Materials and Methods: Patients with confirmed EGFR T790M after disease progression of prior EGFR-TKI were enrolled and administered osimertinib 80 mg daily. The primary effectiveness outcome was progression-free survival, with time-to-treatment discontinuation, treatment and adverse effects leading to treatment discontinuation, and overall survival being the secondary endpoints. Results: A total of 558 individuals were enrolled, and 55.2% had investigator-assessed responses. The median progression-free survival was 14.2 months (95% confidence interval [CI], 13.0 to 16.4), and the median time-to-treatment discontinuation was 15.0 months (95% CI, 14.1 to 15.9). The median overall survival was 36.7 months (95% CI, 30.9 to not reached). The benefit with osimertinib was consistent regardless of the age, sex, smoking history, and primary EGFR mutation subtype. However, hepatic metastases at the time of diagnosis, the presence of plasma EGFR T790M, and the shorter duration of prior EGFR-TKI treatment were poor predictors of osimertinib treatment. Ten patients (1.8%), including three with pneumonitis, had to discontinue osimertinib due to severe adverse effects. Conclusion Osimertinib demonstrated its clinical effectiveness and survival benefit for EGFR T790M mutation–positive in Korean patients with no new safety signals.

We aimed to develop evidence-based recommendations for treating axial spondylarthritis (axSpA) in Korea. The development committee was constructed, key clinical questions were determined, and the evidence was searched through online databases including MEDLINE, Embase, Cochrane, KoreaMed, and KMbase. Systematic literature reviews were conducted, quality of evidence was determined, and draft recommendations were formulated according to the Grading of Recommendations Assessment, Development, and Evaluations methodology. Recommendations that reached 80% consensus among a voting panel were finalized. Three principles and 21 recommendations were determined. Recommendations 1 and 2 pertain to treatment strategies, regular disease status assessment, and rheumatologist-steered multidisciplinary management. Recommendations 3 and 4 strongly recommend patient education, exercise, and smoking cessation. Recommendations 5~12 address pharmacological treatment of active disease using nonsteroidal anti-inflammatory drugs, glucocorticoids, sulfasalazine, biologics, and Janus kinase inhibitors.Recommendations 13~16 address treatment in stable disease. We suggest against spa and acupuncture as therapies (Recommendation 17). Recommendations 18 and 19 pertain to total hip arthroplasty and spinal surgery. Monitoring of comorbidities and drug toxicities are recommended (Recommendations 20 and 21). Recommendations for axSpA treatment in a Korean context were developed based on comprehensive clinical questions and evidence. These are intended to guide best practice in the treatment of axSpA.